

(II)

or a pharmaceutically acceptable salt thereof, wherein


R^1 is hydrogen, halogen, -OH, -OR^4, -$N(R^4)_2$, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl;

R^2 is alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl;

R^3 is hydrogen, halogen, -OH, -NH_2, -NH(C1-C3alkyl) or C1-C3alkyl; and

each R^4 is independently hydrogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl.

[0005a] One embodiment provides a compound having the structure of Formula (Ic),



(Ic)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen, halogen, -OH, -OR^5, -$N(R^5)_2$, alkyl, carbocyclyl, heterocyclyl, optionally substituted aryl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl;

R^2 is alkyl, optionally substituted carbocyclyl, heterocyclyl, optionally substituted aryl, heteroaryl, optionally substituted carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl;

R^3 is hydrogen;

R^4 is hydrogen, optionally substituted C_1-C_4alkyl, C_1-C_4alkene, C_1-C_4alkyne, halogen, or –CN; and

each R^5 is independently hydrogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl.

[0006] One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. One embodiment provides a pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0006a] One embodiment provides a pharmaceutical composition comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

[0006b] One embodiment provides a method for inhibiting histone demethylase enzyme *in vitro* comprising contacting the histone demethylase enzyme with a compound as disclosed herein.

[0007] One embodiment provides a method for inhibiting a histone demethylase enzyme comprising contacting the histone demethylase enzyme with a compound of Formula (I). One embodiment provides a method for inhibiting a histone demethylase enzyme comprising contacting the histone demethylase enzyme with a compound of Formula (II).

[0008] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof. One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

[0008a] One embodiment provides use of a composition comprising a compound as described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a subject in need thereof.

[0008b] One embodiment provides use of a composition comprising a compound as disclosed herein, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating pancreatic cancer in a subject in need thereof.


INCORPORATION BY REFERENCE

[0009] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

CLAIMS

We Claim:

1. A compound having the structure of Formula (Ic),



(Ic)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen, halogen, -OH, -OR^5, -$N(R^5)_2$, alkyl, carbocyclyl, heterocyclyl, optionally substituted aryl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl;

R^2 is alkyl, optionally substituted carbocyclyl, heterocyclyl, optionally substituted aryl, heteroaryl, optionally substituted carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl;

R^3 is hydrogen;

R^4 is hydrogen, optionally substituted C_1-C_4alkyl, C_1-C_4alkene, C_1-C_4alkyne, halogen, or –CN; and

each R^5 is independently hydrogen, alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, carbocyclylalkyl, heterocyclylalkyl, aralkyl, or heteroarylalkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is alkyl.

3. The compound of any one of claims 1-2, or a pharmaceutically acceptable salt thereof, wherein R^2 is methyl.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is optionally substituted carbocyclyl or carbocyclylalkyl.

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R^2 is optionally substituted -(C_1-C_6alkylene)carbocyclyl.

6. The compound of claim 4 or 5, or a pharmaceutically acceptable salt thereof, wherein carbocyclyl is 1,2,3,4-tetrahydronaphthyl optionally substituted with one or more groups selected from halogen, hydroxy, -CN, alkyl, alkoxy, alkylamino, aryl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl.

7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein the (C_1-C_6alkylene) is a C_1alkylene, or a C_2alkylene.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is heterocyclyl or heterocyclylalkyl.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is heteroaryl or heteroarylalkyl.

10. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R^2 is optionally substituted aryl or aralkyl.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein the aralkyl is -(C_1-C_6alkylene)aryl.

12. The compound of claim 10 or 11, or a pharmaceutically acceptable salt thereof, wherein the aryl is a phenyl optionally substituted with one or more groups selected from halogen, hydroxy, -CN, alkyl, alkoxy, alkylamino, aryl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl.

13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein (C_1-C_6alkylene) is C_1alkylene, or a C_2alkylene.

14. The compound of claim 10 or 11, or a pharmaceutically acceptable salt thereof, wherein aryl is naphthyl optionally substituted with one or more groups selected from

halogen, hydroxy, -CN, alkyl, alkoxy, alkylamino, aryl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl.

15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein (C_1-C_6alkylene) is C_1alkylene, or a C_2alkylene.

16. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen or aryl.

17. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen.

18. The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein R^1 is optionally substituted aryl.

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein the aryl is a phenyl optionally substituted with one or more groups selected from halogen, hydroxy, -CN, alkyl, alkoxy, -O-(cycloalkylalkyl), alkylamino, aryl, carbocyclyl, heterocyclyl, carbocyclylalkyl, and heterocyclylalkyl.

20. The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein the phenyl is substituted with one or more groups selected from halogen, alkoxy, or -O-(cycloalkylalkyl).

21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydrogen.

22. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R^4 is –CN.

23. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R^4 is C_1-C_4alkene, or C_1-C_4alkyne.

24. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R^4 is halogen.

25. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R^4 is optionally substituted C_1-C_4alkyl.

26. The compound of claim 25, or a pharmaceutically acceptable salt thereof, wherein R^4 is optionally substituted C_1-C_4alkyl, and the alkyl is substituted with at least one fluoro.

27. The compound of claim 26, or a pharmaceutically acceptable salt thereof, wherein R^4 is CH_2F, CHF_2, or CF_3.

28. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein R^4 is CF_3.

29. A pharmaceutical composition comprising a compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

30. A method for inhibiting histone demethylase enzyme *in vitro* comprising contacting the histone demethylase enzyme with a compound of any of the preceding claims.

31. Use of a composition comprising a compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating pancreatic cancer in a subject in need thereof.